15:40 , May 10, 2019 |  BC Extra  |  Clinical News

Polyphor valuation cut in half on halted Phase IIIs of antibiotic murepavadin

Polyphor lost CHF12.27 (48%) to CHF13.38 on Friday after announcing late Thursday that it suspended enrollment in a pair of Phase III trials of pneumonia antibiotic murepavadin (POL7080) after observing a higher-than-expected incidence of acute...
23:12 , Apr 24, 2019 |  BC Extra  |  Company News

Management tracks: Portola, Assembly, Entasis

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said John Curnutte will retire as EVP and head of R&D on May 17 after eight years at the hematology company. SVP of Research Pamela Conley will lead research activities, effective...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:53 , Mar 20, 2019 |  BC Innovations  |  Translation in Brief

Sangamo’s ZFN linkers finger new options

Sangamo is using new linkers to expand the structural variety of the ZFNs it designs and increase the odds of finding ZFNs with high editing efficiency and specificity for their targets. Conventional zinc finger nucleases...
14:28 , Mar 19, 2019 |  BC Innovations  |  Distillery Therapeutics

RSV F protein-based nanoparticle vaccine for RSV infection

DISEASE CATEGORY: Infectious disease INDICATION: Respiratory syncytial virus (RSV) Mouse and non-human primate studies suggest an RSV F protein-based nanoparticle vaccine could help prevent RSV infection. The self-assembling nanoparticles consist of a core of 12...
02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
22:27 , Oct 19, 2018 |  BC Extra  |  Politics & Policy

FDA asks peers to globalize generic drug development

FDA is calling on international regulatory authorities to develop harmonized guidelines on scientific and technical standards for generic drugs that would allow manufacturers to use the same data and applications to gain approval across multiple...
18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Rat and mouse studies suggest inhibiting the long non-coding RNA (lncRNA) NEAT1 could help treat neointimal hyperplasia. In carotid artery samples from a rat model of angioplasty-associated neointimal hyperplasia, NEAT1 levels were higher...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...